Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Critical Test for FDA's Critical Path Initiative

This article was originally published in RPM Report

Executive Summary

FDA wants to reverse the deline in NDA approvals; the agency may have a key ally at a new center in Arizona.

You may also be interested in...

A Brief But Memorable Tenure: Former US FDA Commissioner Lester Crawford Dies At 83

Crawford’s time as permanent FDA commissioner lasted less than three months and ended in scandal, but with that stint and his longer stretches as acting commissioner, he oversaw the agency through several historic moments that continue to influence the current regulatory environment.

Critical Path Institute’s New Business Model: An Interview With CEO Compton

After six months on the job, Carolyn Compton, the institute’s new chief executive, has overhauled the funding rules to allow fees from big pharma to cover overhead as government funding dries up. Successor to founder Raymond Woosley, who retired last year, Compton shares her vision for securing the institute’s finances for the future amid tough economic times.

TB Drug Development: An Attractive Public Health Project for FDA

FDA is joining in the push for new tuberculosis treatments, with Commissioner Hamburg lending support for a renewed development effort. The challenge is to translate podium appearances into changes that will make for a more attractive development pathway. The primary goal is to find a way to study multi-drug regimens, including regimens with more than one investigational compound. FDA is engaging on that thorny regulatory issue.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts